ArticleEuropean journal of medical research2025
Identification of a chromatin-modifying gene-histone lysine N-methyl transferase (KMT2C/MLL3) as a potential immunomodulator oncogene in Indian pancreatic cancer patients.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune signaling as a determinant of cellular identity and tissue function.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundDue to lack of early biomarkers, pancreatic cancer (PanCa), often manifests late, with few treatment options and poor prognosis, Although epigenetic regulators-particularly lysine methyltransferases like KMT2C-are becoming increasingly linked to cancer biology, their function in PanCa is still poorly understood.
objectivesThis study aims to investigate KMT2C's mutational and expression landscape in Indian PanCa patients, to explore it's possible role in carcinogenesis and immune modulation, and to assess its druggability through computational docking and dynamic simulations.
methodsClinical samples from Indian PanCa patients were used for differential expression and mutation studies. Differential expression, methylation, mutation, and immune cell infiltration profiling were also conducted using public databases (TCGA, GEO, CPTAC, and CCLE). Regulatory networks, scRNA-seq analysis, and protein-protein interaction networks were mapped. To evaluate ligand binding to KMT2C, molecular docking and 100-ns molecular dynamics simulations were used.
resultsKMT2C was overexpressed and exhibited a significantly higher mutational frequency (62.5%) in Indian PanCa samples in contrast with Western cohorts. Its role in immune suppression was implicated by positive correlations observed between KMT2C expression and several. immune-checkpoint receptor expression and regulatory T-cell infiltration. KMT2C was connected by functional enrichment to inositol phosphate metabolism and chromatin remodelling. The therapeutic potential of protodioscin was suggested by its strong binding affinity to KMT2C and the formation of stable interactions confirmed by MD simulations.
conclusionThis study suggests KMT2C to be a putative oncogene in Indian PanCa patients in contrast with Western PanCa patients, with immunomodulatory effects and therapeutic potential, implicating its role as a promising biomarker, requiring additional clinical validation, emphasizing the necessity of ethnically informed precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.